PolyPid's Q1 2025: Key Contradictions in Pricing, FDA Readiness, and Clinical Protocols

Pricing strategy for D-PLEX100, number of vials per procedure in SHIELD 2, preparation for FDA inspection, expected timeframe for top line data release, and FDA inspection readiness and capacity are the key contradictions discussed in PolyPid Ltd.'s latest 2025Q1 earnings call.



SHIELD 2 Trial Progress:
- PolyPid completed enrollment of the SHIELD 2 Phase 3 trial, assessing D-PLEX100 for preventing surgical site infections, with a final count of 800 patients.
- The trial was concluded at the lowest sample size reassessment stop, 800 patients, after the minimum planned number of patients, indicating potential positive efficacy signals.

Potential Market Size and Partnership Opportunities:
- The potential market size for D-PLEX100 in the United States is over 12 million total surgeries annually, with approximately 4.4 million being abdominal soft tissue surgeries and additional 2.1 million abdominal procedures.
- The company is actively exploring partnership opportunities, particularly in the U.S., with multiple potential partners in advanced discussions.

Financial Stability and Runway Extension:
- As of March 31, 2025, PolyPid had $8 million in cash, sufficient to fund operations into the third quarter of 2025.
- The company expects that data-triggered warrants from a recent financing could provide an additional $27 million, potentially extending its runway beyond anticipated NDA approval.

Increased Surgical Site Infections Post-COVID:
- A CDC report showed a 3% increase in surgical site infections (SSIs) across all surgeries in 2023 compared to 2022, indicating a post-COVID rebound in SSI rates.
- This trend underscores the potential market need for D-PLEX100 to prevent surgical site infections.